Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F16%3AN0000071" target="_blank" >RIV/00209805:_____/16:N0000071 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14740/16:00087634 RIV/00216208:11110/16:10327760 RIV/00216208:11150/16:10327760 RIV/61989592:15110/16:33161335 and 3 more
Result on the web
<a href="https://ar.iiarjournals.org/content/anticanres/36/9/4955.full.pdf" target="_blank" >https://ar.iiarjournals.org/content/anticanres/36/9/4955.full.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/anticanres.11063" target="_blank" >10.21873/anticanres.11063</a>
Alternative languages
Result language
angličtina
Original language name
Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients
Original language description
Background: In metastatic colorectal cancer (mCRC), panitumumab is generally considered to be ineffective after the progression on cetuximab therapy. However, few studies have demonstrated that a small subset of mCRC patients may benefit from panitumumab in this setting. Patients and Methods: In our study, wild-type KRAS mCRC patients, enrolled into the nationwide Czech registry CORECT between January 2007 and December 2012, were screened for panitumumab therapy after progression on cetuximab. Results: We identified 26 mCRC in the registry with well documented progression on cetuximab in combination with irinotecan-based chemotherapy (FOLFIRI or irinotecan alone) who received panitumumab monotherapy. Partial response (PR) was achieved in 3 (11.5%) patients and stable disease (SD) in 7 (26.9%) patients after 8 weeks of therapy. Thirteen (50.0%) patients had evidence of progressive disease (PD) and in 3 (11.5%) cases response was not available. Furthermore, we confirmed that higher expression levels of newly described biomarker, miR-31-5p, in tumor are significantly associated with shorter progression-free survival (PFS) in patients treated with cetuximab (p=0.038); however, we did not observe association between miR-31-5p and response to panitumumab in mCRC patients after progression on cetuximab. Conclusion: It remains possible that a subset of mCRC patients may benefit from panitumumab after progression on cetuximab.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
—
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Anticancer research
ISSN
0250-7005
e-ISSN
—
Volume of the periodical
36
Issue of the periodical within the volume
9
Country of publishing house
GR - GREECE
Number of pages
5
Pages from-to
4955-4959
UT code for WoS article
000384001800083
EID of the result in the Scopus database
2-s2.0-84991696540